Literature DB >> 11865970

Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects.

Sambamoorthy Bolla1, Ramesh R Boinpally, Srinivasu Poondru, Rambhau Devaraj, Bhaskara R Jasti.   

Abstract

In most Wuchereria bancrofti and Brugia malayi infections, the microfilaria are found in the blood in greatest number between 10 p.m. and 2 a.m., indicating that chronotherapy may be beneficial in treating such infections. This study reports the influence of time of administration on the pharmacokinetics of diethylcarbamazine (DEC) in healthy volunteers. The study was conducted in 12 healthy volunteers by administering a 150 mg single oral dose of diethylcarbamazine citrate at 0600 or 1800 h in a balanced crossover design with the approval of an institutional ethics committee. The subjects fasted for about 10 hours before and 3 hours after drug treatment. Blood samples were collected at predetermined time intervals, and the drug content in the serum was estimated using HPLC with an electrochemical detector. Pharmacokinetic analysis was performed using noncompartmental methods employing WinNonlin (version 3.1), and the means of various pharmacokinetic parameters were compared for any dosing time-related changes using a paired t-test at a probability level of 95%. The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h. None of the parameters was significantly changed (p > 0.05) as a function of time of administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865970     DOI: 10.1177/00912700222011247

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Molecular evidence for apoptosis in microfilariae of Wuchereria bancrofti induced by diethylcarbamazine.

Authors:  C A Peixoto; A C O Santos; C F J Ayres
Journal:  Parasitol Res       Date:  2008-05-23       Impact factor: 2.289

2.  LC-MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: Application to a clinical pharmacokinetic study.

Authors:  Yashpal S Chhonker; Constant Edi; Daryl J Murry
Journal:  J Pharm Biomed Anal       Date:  2017-12-24       Impact factor: 3.935

Review 3.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

4.  Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.

Authors:  Constant Edi; Catherine M Bjerum; Allassane F Ouattara; Yashpal S Chhonker; Louis K Penali; Aboulaye Méité; Benjamin G Koudou; Gary J Weil; Christopher L King; Daryl J Murry
Journal:  PLoS Negl Trop Dis       Date:  2019-05-20

5.  Therapy and Prevention for Human Toxocariasis.

Authors:  Jean-François Magnaval; Emilie Bouhsira; Judith Fillaux
Journal:  Microorganisms       Date:  2022-01-22

6.  Population Pharmacokinetics of Diethylcarbamazine in Patients with Lymphatic Filariasis and Healthy Individuals.

Authors:  Veenu Bala; Yashpal S Chhonker; Abdullah Alshehri; Constant Edi; Catherine M Bjerum; Benjamin G Koudou; Christopher L King; Daryl J Murry
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.938

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.